DRI Healthcare Trust (TSE:DHT.UN) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of DRI Healthcare Trust (TSE:DHT.UN) have been assigned a consensus rating of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is C$18.00.

A number of brokerages have recently commented on DHT.UN. Raymond James lowered their price objective on DRI Healthcare Trust from C$23.00 to C$22.00 in a research report on Wednesday, November 13th. Scotiabank raised their price target on DRI Healthcare Trust from C$21.00 to C$22.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th.

DRI Healthcare Trust Stock Up 0.6 %

DRI Healthcare Trust stock opened at C$8.70 on Thursday. DRI Healthcare Trust has a twelve month low of C$10.39 and a twelve month high of C$17.43. The stock’s fifty day simple moving average is C$13.39 and its 200-day simple moving average is C$13.40.

DRI Healthcare Trust Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 18th. Investors of record on Friday, October 18th were issued a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a yield of 3.91%. The ex-dividend date was Friday, September 27th. DRI Healthcare Trust’s dividend payout ratio is currently -920.00%.

About DRI Healthcare Trust

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.